ArticleFrontiers in medicine2025
Identifying key genes associated with recurrence in non-small cell lung cancer through TCGA and single-cell analysis.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Sorting nexin 9 expression and prognostic implications in lung adenocarcinoma: integrative bioinformatic andTranslational cancer research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aims to mine the TCGA database for differentially expressed genes in recurrent lung cancer tissues, determine the relationship between these recurrent genes and lung cancer at the single-cell level, and identify potential targets for lung cancer treatment. Methods: Data for lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC) were obtained from the TCGA database and grouped based on clinical recurrence information. Single-cell data from GSE131907 were downloaded from the GEO database. R was utilized to screen for differentially expressed genes (DEGs), followed by weighted gene co-expression network analysis (WGCNA) of these DEGs. Additionally, the GSEA database was employed to visualize differential pathways and identify key genes. The relationship between the expression of these key genes and lung cancer recurrence was validated using the GSE131907 single-cell dataset. Results: A total of 2,239 differentially expressed genes were identified in the LUAD dataset, while 3,404 differentially expressed genes were found in the LUSC dataset. WGCNA revealed that the lapis lazuli module gene set was associated with recurrence. Validation at the single-cell level indicated that the FOXI1, FOXB1, and KCNA7 genes were linked to lung cancer progression. Conclusion: The differentially expressed genes primarily influence NSCLC recurrence through involvement in biological processes related to metabolism and hormone secretion pathways. Notably, the KCNA7 and FOX gene families were identified as critical for NSCLC recurrence. This study highlights specific genes within proliferation and cell cycle pathways as key therapeutic targets for managing NSCLC recurrence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.